Strong organic growth and profitability were driven by Prosthetics & Neuro Orthotics, with six new product launches and robust free cash flow. Guidance for 2026 was narrowed, and a new $10M share buyback was initiated. Patient Care sales lagged in Europe but showed progress in Americas and APAC.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.